• Explore /
  • Poster
  • / DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC<span style="color: #2e3133; font-family: Helvetica; font-size: large;" size="4" face="Helvetica" color="#2e3133"></span>—<span style="color: #2e3133; font-family: Helvetica; font-size: large;" size="4" face="Helvetica" color="#2e3133"></span>Results of the preplanned feasibility interim analysis.

DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.

Abstract Poster

Authors

Konrad Klinghammer

Konrad Friedrich Klinghammer

Charite Comprehensive Cancer Center, Berlin, Germany

Konrad Friedrich Klinghammer , Thomas Christoph Gauler , Carmen Stromberger , Grzegorz Kofla , Maike de Wit , Johannes Gollrad , Izabella Rauer , Peter Martus , Inge Tinhofer , Volker Budach , Ulrich Keilholz , Susen Burock

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT03624231

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6574)

DOI

10.1200/JCO.2020.38.15_suppl.6574

Abstract #

6574

Poster Bd #

235

Abstract Disclosures

Similar Posters

First Author: Ulrich Keilholz

First Author: Hyung-Don Kim

First Author: Jenny F. Seligmann

First Author: Ho Yeong Lim